Women at risk for cervical disease, the technology was able to detect cervical cancer up toTWO YEARS EARLIER than conventional modalities, according to published reports . I find this most interesting.It is also non invasive..I see a tie here that might be advantages to both.I have tied two other companies to gether that had simalar connections and it worked out.Imagine having the ability to find cervical cancer two years earlier and then being ablr to cure it.. just a thought..
druggy25 Why dont you give it up? Your immune system cant handle that much evil forever..Happy holiday..
With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers""" who were increasing their holdings considerably """(or already accumulated large positions). Thats' important...follow the money!!
Now, we’re going to analyze the fresh action surrounding Inovio Pharmaceuticals Inc (NASDAQ:INO).
What have hedge funds been doing with Inovio Pharmaceuticals Inc (NASDAQ:INO)?
At the end of the third quarter, a total of 7 of the hedge funds tracked by Insider Monkey held long positions in this stock, unchanged from the previous quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).
According to Insider Monkey’s hedge fund database, Sabby Capital, managed by Hal Mintz, holds the largest position in Inovio Pharmaceuticals Inc (NASDAQ:INO). The fund has reported a $4.3 million position in the stock, comprising 0.2% of its 13F portfolio. The second largest stake is held by Citadel Investment Group, managed by Ken Griffin, which holds a $2.4 million stake; less than 0.1% of its 13F portfolio is allocated to the stock. Remaining professional money managers with similar optimism comprise Israel Englander’s Millennium Management and Glenn Russell Dubin’s Highbridge Capital Management.
November 25, 2015 by Roger Valet in Market Indices · 0 Comment
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) encountered a drop of 4% or -594,828 shares in the short positions. The number dropped from 14,896,481 on October 30,2015 to 14,301,653 on November 13,2015. The final interest is 21% of the floated stock. The days to cover figure of 10 can be arrived using the average daily exchange of 1,368,577 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on November 24th after Market close.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 1 by 5 Wall Street Analysts. 5 analysts have added the shares in their list of strong buys. Shorts IQ 's even lower..
And a good one V.. . the chart shows you when the market maker wants to bring the stock down in an orderly manner by making lower highs on minimum volume. when you run up to that resistance line with a low volume you can be sure it will turn on that line as this one has so far today. but as I said we are hanging right on that line right there . we need to break through on" volume" right now we're just day trading.called ..back and fill...As you state,our day will come..